Immunomedics, Inc.  

(Public, NASDAQ:IMMU)   Watch this stock  
Find more results for IMMU
4.96
-0.10 (-1.98%)
After Hours: 4.97 +0.01 (0.15%)
Feb 22, 4:11PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.92 - 5.09
52 week 1.91 - 5.89
Open 5.01
Vol / Avg. 2.15M/4.56M
Mkt cap 498.57M
P/E     -
Div/yield     -
EPS -0.72
Shares 106.08M
Beta 1.67
Inst. own 59%
Feb 1, 2017
Q2 2017 Immunomedics Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -6363.89% -1828.99%
Operating margin -3998.14% -1825.04%
EBITD margin - -1802.22%
Return on average assets -209.23% -72.68%
Return on average equity - -
Employees 131 -
CDP Score - -

Address

300 the American Rd
MORRIS PLAINS, NJ 07950-2460
United States - Map
+1-973-6058200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Officers and directors

David M. Goldenberg Chief Scientific Officer, Chief Patent Officer, Director
Age: 78
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Cynthia L. Sullivan President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Jason M. Aryeh Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Michael R. Garone Chief Financial Officer, Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert Forrester Independent Director
Age: 52
Bio & Compensation  - Reuters
Brian A. Markison Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Bob Oliver Independent Director
Bio & Compensation  - Reuters